Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

Atrial Fibrillation Clinical Trial

Official title:

Temporary Autonomic Blockade to Prevent Atrial Fibrillation After Cardiac Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02498769
• Other study ID #: Pro00061607
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: September 2015
• Est. completion date: December 1, 2018

Study information

• Verified date: February 2019
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, the investigators aim to determine whether injecting botulinum toxin into epicardial fat pads is efficacious and safe for decreasing postoperative atrial fibrillation (POAF) after cardiac surgery. The investigators will test the hypothesis that botulinum toxin injected into the epicardial fat pads reduces POAF and length of stay (LOS) without increasing adverse events. This will be a prospective randomized trial of 130 patients undergoing coronary artery bypass graft (CABG), valve surgery or CABG + valve surgery with cardiopulmonary bypass. Patients will be randomized to receive either botulinum toxin (50 units per fat pad, n=65) or normal saline/placebo (1 mL per fat pad, n=65) injected into epicardial fat pads. All patients will receive standardized anesthetic, surgical, and post-surgical care. The primary outcome in this study will be time to occurrence of in-hospital POAF. Based on previous work and a pilot trial showing a pronounced reduction (relative risk reduction 77%) in POAF after injecting botulinum into the epicardial fat pads, the investigators anticipate a significant reduction in the risk for POAF with epicardial botulinum in this cohort, which includes valve surgery patients.

Description:

Purpose of the study: A pilot study to determine whether injecting botulinum toxin into epicardial fat pads is efficacious and safe for decreasing postoperative atrial fibrillation (POAF) after cardiac surgery

Hypothesis to be tested: Botulinum toxin injected into the epicardial fat pads reduces POAF.

Design and Procedures: This will be a prospective randomized pilot trial of 130 patients undergoing coronary artery bypass graft (CABG), valve surgery or CABG + valve surgery via median sternotomy with cardiopulmonary bypass. Patients <50 years of age, with chronic atrial fibrillation, prior cardiac surgery, EF<25%, preoperative inotropic support, hepatic or renal failure, known sensitivity to botulinum toxin, debilitating neuromuscular disease, or those with a history of atrioventricular block will be excluded from the study. Prior to surgery, all patients will have baseline Mini-Mental State Examination (MMSE) and blood sampling from an indwelling arterial line or venipuncture for measurement of inflammatory and genomic markers. Half of the patients will be randomized to receive injection of epicardial botulinum toxin in addition to standard of care, as described below. The other half will receive epicardial injection of normal saline.

Institution of cardiopulmonary bypass will be performed according to the routine surgical protocol. After instituting CPB, botulinum toxin (or normal saline) injections will be performed by the surgeon. This dose was selected given the prior report of its effectiveness in preventing POAF after cardiac surgery in a small pilot study.(Pokushalov et al., 2014) After completion of surgery and separation from CPB, patients will proceed along the institutional Cardiac Surgical Caremap. All patients will be monitored with continuous ECG (telemetry) until hospital discharge. POAF will be diagnosed by telemetry or 12-lead ECG, and will be defined as new-onset if it occurs postoperatively at any time before hospital discharge. POAF, if it occurs, will be treated as per routine of care. POAF will be defined as any detectable atrial fibrillation before discharge that lasts >30 seconds. On postoperative day (POD) 4, a member of the study team will visit each patient to administer the MMSE and capture a 5-minute ECG with a Holter monitor. In addition, patients will be contacted monthly for 4 months and at one year after surgery for follow up, and medical records will be reviewed for evidence of readmissions, arrhythmias, or other adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 130
• Est. completion date: December 1, 2018
• Est. primary completion date: September 28, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years to 90 Years

Eligibility

Inclusion Criteria:

• Undergoing cardiac surgery with cardiopulmonary bypass via median sternotomy

• coronary artery bypass graft (CABG)

• valve surgery

• CABG + valve surgery

Exclusion Criteria:

• < 50years of age

• > 90years of age

• chronic AF or AF at the time of screening

• preoperative heart block (second degree or greater)

• LVEF < 25%

• renal failure

• hepatic failure

• known sensitivity to Botulinum toxin

• debilitating neuromuscular disease

• preoperative need for inotropes/vasopressors or intra-aortic balloon pump

• planned MAZE procedure

• history of catheter ablation for AF

• use of Vaughan-Williams class I or III drugs within 5 elimination half lives (or within 2 months for amiodarone)

• undergoing minimally-invasive cardiac surgery

• prior cardiac surgery

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Drug:
• Botulinum Toxin Type A
The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
• Placebo

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (3)

Lead Sponsor	Collaborator
Joseph Mathew, M.D.	American Heart Association, Foundation for Anesthesia Education and Research

Country where clinical trial is conducted

United States, 

References & Publications (2)

Oh S, Choi EK, Zhang Y, Mazgalev TN. Botulinum toxin injection in epicardial autonomic ganglia temporarily suppresses vagally mediated atrial fibrillation. Circ Arrhythm Electrophysiol. 2011 Aug;4(4):560-5. doi: 10.1161/CIRCEP.111.961854. Epub 2011 Jun 9. — View Citation

Pokushalov E, Kozlov B, Romanov A, Strelnikov A, Bayramova S, Sergeevichev D, Bogachev-Prokophiev A, Zheleznev S, Shipulin V, Salakhutdinov N, Lomivorotov VV, Karaskov A, Po SS, Steinberg JS. Botulinum toxin injection in epicardial fat pads can prevent recurrences of atrial fibrillation after cardiac surgery: results of a randomized pilot study. J Am Coll Cardiol. 2014 Aug 12;64(6):628-9. doi: 10.1016/j.jacc.2014.04.062. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time to In-hospital Post-operative Atrial Fibrillation (POAF)	Patients will be seen on a daily basis and the timing of POAF compared between groups. The occurrence of in-hospital POAF will be tracked throughout the hospitalization (up to two weeks) and the time from surgery to the first and subsequent episodes of POAF recorded and compared between groups. POAF will be determined by ECG or telemetry.	From the time of ICU arrival until the time of first documented POAF, or discharge whichever came first, assessed up to 2 weeks
Secondary	Number of Participants With In-hospital POAF	Patients will be seen on a daily basis and the occurrence of POAF compared between groups.	The incidence of in-hospital POAF will be tracked throughout the hospitalization (up to two weeks)
Secondary	Length of Stay	Total and ICU length of stay will be determined by examining medical records for the length of inpatient hospitalization, assessed over the entire study period (up to two years). ICU and hospital LOS will be recorded and compared between groups	ICU length of stay was measured from time of surgery to time of ICU discharge. Post-operative length of stay was measured from time of surgery to time of hospital discharge.
Secondary	Number of Participants With Adverse Events	The total number of postoperative complications (including infectious, neurologic, and renal complications, as well as mortality) and the number of subjects with complications will be monitored and compared between groups.	Adverse events from the time of surgery through hospital discharge, up to 2 weeks